Clinical Trial Update: S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer [Phase 2]

View source ↗

Summary

The Phase 2 trial S0225 evaluating capecitabine in patients who underwent surgery for locally recurrent or persistent head and neck squamous cell carcinoma has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Hypopharynx
• Squamous Cell Carcinoma of the Larynx
• Squamous Cell Carcinoma of the Lip and Oral Cavity
• Squamous Cell Carcinoma of the Oropharynx
• Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity | Phase 2 | Status: WITHDRAWN